Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Apr 2020 07:00 AM
RNS
Subscription to raise £2 million
26 Mar 2020 11:05 AM
RNS
Second Price Monitoring Extn
26 Mar 2020 11:00 AM
RNS
Price Monitoring Extension
24 Mar 2020 02:06 PM
RNS
Second Price Monitoring Extn
24 Mar 2020 02:00 PM
RNS
Price Monitoring Extension
16 Mar 2020 04:42 PM
RNS
Second Price Monitoring Extn
16 Mar 2020 04:38 PM
RNS
Price Monitoring Extension
10 Mar 2020 07:00 AM
RNS
Shareholder/Investor Meeting and Presentation
13 Feb 2020 07:00 AM
RNS
Notice of Results
11 Feb 2020 07:00 AM
RNS
Share Incentive Plan/Issue of Equity
03 Feb 2020 07:00 AM
RNS
Avacta and Daewoong Agreement
29 Jan 2020 02:45 PM
RNS
Holding(s) in Company
28 Jan 2020 07:00 AM
RNS
Successful initial proof-of-concept
23 Jan 2020 07:00 AM
RNS
Trading Update
21 Jan 2020 07:00 AM
RNS
Director Appointment
08 Jan 2020 07:00 AM
RNS
Avacta and Daewoong Establish Joint Venture
26 Nov 2019 09:00 AM
RNS
Holding(s) in Company
22 Nov 2019 08:41 AM
RNS
Director/PDMR Shareholding
13 Nov 2019 07:00 AM
RNS
LG Chem Life Sciences Expands Partnership
11 Nov 2019 07:00 AM
RNS
Holding(s) in Company
08 Nov 2019 06:30 PM
RNS
Holding(s) in Company
08 Nov 2019 06:26 PM
RNS
Holding(s) in Company
07 Nov 2019 01:00 PM
RNS
Holding(s) in Company
07 Nov 2019 11:00 AM
RNS
Holding(s) in Company
06 Nov 2019 02:30 PM
RNS
Holding(s) in Company
04 Nov 2019 01:18 PM
RNS
Result of General Meeting
18 Oct 2019 12:06 PM
RNS
Proposed Placing & Subscription to raise up to £9M
18 Oct 2019 12:05 PM
RNS
Interim Results for the Period Ended 31 July 2019
10 Oct 2019 07:00 AM
RNS
Collaboration with ADC Therapeutics
05 Aug 2019 09:05 AM
RNS
Second Price Monitoring Extn
05 Aug 2019 09:00 AM
RNS
Price Monitoring Extension
29 Jul 2019 07:00 AM
RNS
Avacta's CEO to Present at Biotech Investor Day
20 Jun 2019 07:00 AM
RNS
Avacta and Selexis Partner to Develop Cell Line
19 Jun 2019 07:00 AM
RNS
Turner Pope Investor Evening
12 Jun 2019 07:00 AM
RNS
Avacta's CSO to Present at Major US Conference
10 Jun 2019 07:00 AM
RNS
Avacta hits Clinical Candidate Selection Milestone
03 Jun 2019 07:00 AM
RNS
TMAC Programme Accelerates
23 Apr 2019 03:48 PM
RNS
Issue of Equity
12 Apr 2019 02:46 PM
RNS
Holding(s) in Company
09 Apr 2019 07:00 AM
RNS
Interim Results
08 Mar 2019 12:14 PM
RNS
Issue of Equity
06 Feb 2019 12:27 PM
EQS
Avacta (AVCT): A second wake-up call for the ma...
04 Feb 2019 07:00 AM
RNS
Moderna Exercises Exclusive Product License Option
28 Jan 2019 07:00 AM
RNS
Director Appointment
21 Jan 2019 03:40 PM
RNS
Result of Annual General Meeting
21 Jan 2019 07:00 AM
RNS
AGM Business Update and Notice of Results
18 Jan 2019 05:08 PM
RNS
Share Incentive Plan/Issue of Equity
18 Jan 2019 10:00 AM
RNS
Change of accounting reference date
09 Jan 2019 11:06 AM
RNS
Holding(s) in Company
07 Jan 2019 02:50 PM
RNS
Director/PDMR Shareholdings

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100

Latest directors dealings